RxDoctor Payments Data

Marie-Helene Saint-Hilaire, MD

Neurology · Boston, MANPI 1245293851

Payments from drug & device makers

$189,304in general payments, 2019–2025

Across 303 payments — averaging $624.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$154K
  • Neurocrine Biosciences, Inc.$13K
  • Acorda Therapeutics, Inc$9K
  • UCB SA$8K
  • MDD US Operations, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $4K from 16 others

What the payments were for

  • Consulting fees$8,16553%
  • Speaking & faculty fees$2211%
  • Travel & lodging$6134%
  • Food & beverage$5,96739%
  • Education$3222%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$189,304 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$90,668
Medicare patients
242
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl11$453,970
AustedoDeutetrabenazine35$335,981
NuplazidPimavanserin Tartrate33$185,467
GocovriAmantadine Hcl47$133,518
Tetrabenazine18$104,965
IngrezzaValbenazine Tosylate12$97,921
RytaryCarbidopa/Levodopa46$91,035
InbrijaLevodopa17$52,362
OngentysOpicapone45$43,445
NeuproRotigotine42$42,909
BotoxOnabotulinumtoxina37$35,097
Entacapone135$26,975
Carbidopa-LevodopaCarbidopa/Levodopa603$25,446
Rasagiline Mesylate112$22,393
Carbidopa-Levodopa ErCarbidopa/Levodopa166$8,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,081$335,98135 claims
Acadia Pharmaceuticals IncNuplazid$253$185,46733 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$12,783$141,36657 claims
MDD US Operations, LLCGocovri$1,143$133,51847 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,053$92,30372 claims
Acorda Therapeutics, IncInbrija$8,825$52,36217 claims
UCB, Inc.Neupro$37$42,90942 claims
AbbVieBotox$471$35,09737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →